Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice

Clinical and Experimental Immunology

Volumn 112, Issue 2, 1998, Pages 188-195

  Shenoy, S ^a   Desch, K ^b   Duffy, B ^b   Thorson, P ^a   Mohanakumar, T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8109 ^*

Author keywords

2m mice; CD4+ cells; Graft rejection; GVHD; MHC class II

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CYTOLYSIS; GRAFT REJECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECIPIENT;

ANIMALS; BETA 2-MICROGLOBULIN; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY TESTING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031802361     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00578.x     Document Type: Article

References (52)

1. Gale RP, Champlin RE. New strategies in bone marrow transplantation. New York: Wiley, 1991.
2. Clift RA, Hansen JA, Thomas ED. Marrow transplantation from donors other than HLA identical siblings. Transplantation 1979; 28:235-42.
3. Parkman R. The application of BMT to the treatment of genetic diseases. Science 1986; 232:373-8.
4. Gale RP. Graft-vs-host disease. Immunol Rev 1985; 88:193-214.
5. Vogelsang GB, Wagner JE. Graft-vs.-host disease. Hematol/Oncol Clinics 1990; 4:625-39.
6. Korngold R. Biology of graft-vs-host disease. Am J Ped Hematol-Oncol 1993; 15:18-27.
7. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-vs.-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18:295-304.
8. Goulmy E. Minor histocompatibility antigens and their role in transplantation. In: Morris PJ, Tilney NL, eds. Transplantation reviews. Philadelphia: W.B. Saunders, Co., 1988:29-54.
9. Mathe G, Pritchard LL, Halle-Pannenko O. Mismatching for minor histocompatibility antigens in bone marrow transplantation; consequences for the development of severe graft-vs-host disease. Transpl Proc 1979; 11:235-9.
10. Rappaport H, Khalil A, Halle-Pannenko O. Histologic sequence of events in adult mice undergoing lethal graft-vs.-host reaction developed across H-2 and/or non-H-2 histocompatibility barriers. Am J Pathol 1979; 96:121-42.
11. Halle-Pannenko O, Pritchard LL, Mathe G. Immunobiology of minor histocompatibility antigens in lethal graft-vs.-host reaction induced in adult mice. In: Thierfelder S, Rodt H, Kolb HJ, eds. Immunobiology of bone marrow transplantations. Berlin: Springer-Verlag, 1980:75.
12. Koller BH, Smithies O. Inactivating the beta-2 microglobulin locus in mouse embryonic stem cells by homologous recombination. PNAS 1989; 86:8932-5.
13. + cytolytic T cells. Nature 1990; 344:742-6.
14. Wettstein PJ, Bailey DW. Immunodominance in the immune response to multiple histocompatibility antigens. Immunogenetics 1982; 16:47-58.
15. Wettstein PJ, Colombo MP. Immunodominance in T cell response to multiple non-H2 histocompatibility antigens. J Immunol 1987; 139:2166-71.
16. Korngold R, Wettstein PJ. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens. J Immunol 1990; 145:4079-88.
17. Yin L, Poirier G, Neth O, Hsuan JJ, Totty NF, Stauss HJ. Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens. Int Immunol 1993; 5:1003-9.
18. + T cells. Science 1990; 248:1227-30.
19. Correa I, Bix M, Liao N, Zijlstra M, Jaenisch R, Raulet D. Most gamma/ delta T cells develop normally in beta2-microglobulin-deficient mice. PNAS 1992; 89:653-7.
20. +, alpha/beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta2-microglobulin, MHC class I-deficient mice. PNAS 1993; 90:2837-41.
21. + cytotoxic T lymphocyte that mediate specific tumor rejection. J Immunol 1993; 151:6283-90.
22. 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I. J Exp Med 1994; 179:661-72.
23. Rodriguez M, Dunkel AJ, Thiemann RL, Leibowitz J, Zijlstra M, Jaenisch R. Abrogation of resistance to Theiler's virus-induced demyelination in H-2b mice deficient in beta2-microglobulin. J Immunol 1993; 151:266-76.
24. Muller D, Koller BH, Whitton JL, LaPan K, Brigman K, Frelinger J. LCMV-specific class II-restricted cytotoxic T cells in beta2-microglobulin-deficient mice. Science 1992; 255:1576-8.
25. Coffman T, Geier S, Ibrahim S et al. Improved renal function in mouse kidney allografts lacking MHC class I antigens. J Immunol 1993; 151:425-35.
26. Zijlstra M, Auchincloss H, Loring J, Chase C, Russell P, Jaenisch R. Skin graft rejection by beta2-microglobulin-deficient mice. J Exp Med 1992; 175:885-93.
27. Hamilton BL, Bevan MJ, Parkman R. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft-vs-host disease due to minor histocompatibility antigens. J Immunol 1981; 126:621-5.
28. Korngold R, Sprent J. Lethal graft-vs-host disease following bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978; 148:1687-98.
29. + cells can either augment or retard GVHD elicited by Ly+-2+ cells in class I-different hosts. J Exp Med 1988; 167:556-69.
30. + T cells to cause lethal graft-vs-host disease across minor histocompatibility barriers in mice. J Exp Med 1987; 165:1552-64.
31. + T cell responses. Transplantation 1992; 9:355-64.
32. + T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol 1987; 139:2511-5.
33. + T cell clones specific for non-H2 antigens. J Immunol 1990; 145:2123-31.
34. Bruley-Rosset M, Miconnet I, Roger T, Seman M, Halle-Pannenko O. Comparison of the repertoire of T cell lines and clones specific for minor histocompatibility antigens derived from immunized mice and from mice developing a graft-vs-host reaction. Transpl Proc 1993; 25:94-95.
35. Bix M, Liao N, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 1991; 349:329-31.
36. Azuma E, Yamamoto H, Kaplan J. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease. J Immunol 1992; 143:1524-9.
37. Sekimata M, Griem P, Egawa K, Rammensee H-G, Takiguchi M. Isolation of human minor histocompatihility peptides. Int Immunol 1992; 4:301-4.
38. Mendonza LM, Paz P, Zuberi A, Christianson G, Roopenian D, Shastri N. Minors held by majors: the H13 minor histocompatibility locus defined as a peptide/MHC class I complex. Immunity 1997; 7:461-72.
39. Nevala WK, Wettstein PJ. The preferential cytolytic T lymphocyte response to immunodominant minor histocompatibility antigen peptides. Transplantation 1996; 62:282-91.
40. b molecules. Transplantation 1997; 64:1323-30.
41. Griem P, Wallny H, Falk K et al. Uneven tissue distribution of minor histocompatibility proteins vs. peptides is caused by MHC expression. Cell 1991; 65:633-40.
42. Wettstein PJ. Murine minor histocompatihility antigens detected by helper T cells. Recognition of an endogenous peptide. J Immunol 1995; 154:2134-43.
43. Berger M, Wettstein PJ, Korngold RT. cell subsets involved in lethal graft-vs.-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 1994; 57:1095-102.
44. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178:27-47.
45. Jaraquemada D, Marti M, Long EO. An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II restricted T cells. J Exp Med 1990; 172:947-54.
46. Colombo MP, Jaenisch R, Wettstein P. Endogenous retroviruses lead to the expression of a histocompatibility antigen detectable by skin graft rejection. Proc Natl Acad Sci USA 1987; 84:193-8.
47. VanEls C, D'Amaro JD, Pool J. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 1992; 35:161-5.
48. deBueger M, Goulmy E. Human minor histocompatibility antigens. Transpl Immunol 1993; 1:28-38.
49. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-vs.-host disease after hone marrow transplantation. New Engl J Med 1996; 334:281-5.
50. Wang W, Meadows LR, denHaan JMM et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269:1588-90.
51. denHaan JMM, Sherman NE, Blokland E et al. Identification of a graft-vs.-host disease-associated human minor histocompatibility antigen. Science 1995; 268:1476-9.
52. + cells for prevention of graft-vs.-host disease after bone marrow transplantation. Transplantation 1994; 1:82-87.